Ductal Carcinoma in Situ of the Breast
Conditions
Keywords
ASAIN
Brief summary
This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy.
Interventions
PROCEDUREAvoiding surgery
Avoiding surgery in hormone-receptor positive atypical ductal hyperplasia and in-situ carcinoma treated with endocrine treatment
Sponsors
Jeong Eon Lee
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1\. Inclusion criteria: 1. Female patients aged ≥35 years. 2. Diagnosed with atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS) on core-needle biopsy, vacuum-assisted biopsy, or excisional biopsy. 3. Immunohistochemistry (IHC) performed on biopsy specimens confirming estrogen receptor (ER), progesterone receptor (PR), and HER2 status; eligible only if the ER Allred total score is ≥7 and HER2 status is negative. 4. All low- and intermediate-grade nuclear grades included; for high-grade lesions, only patients with a Ki-67 index ≤20% are eligible. 5. Lesion not definitely palpable on physical examination at diagnosis. 6. No prior breast surgery for ipsilateral or contralateral breast cancer, and no synchronous contralateral breast cancer. 7. Not diagnosed with pregnancy-associated breast cancer or breast cancer detected during lactation. 8. Negative serum or urine β-hCG prior to enrollment. 9. Provided written informed consent to participate in the study. 2\.
Exclusion criteria
1. Pregnant patients. 2. Patients with clinically significant psychiatric disorders (e.g., major depressive disorder) or those currently receiving psychiatric or antipsychotic medications. 3. Concomitant diagnosis of invasive breast cancer. 4. Evidence of axillary lymph node metastasis. 5. Carriers of BRCA1/2 mutations. 6. Male patients. 7. History of diagnosis or treatment for breast cancer. 8. Presence or history of other malignancies besides breast cancer. 9. Concomitant diagnosis of pleomorphic LCIS.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 5 year ipsilateral breast cancer incidence rate | 5 years after the last patient enrollment | This study aims to evaluate the 5-year invasive ipsilateral breast cancer incidence rate in patients with hormone-receptor positive, HER-2 negative atypical ductal hyperplasia or in-situ carcimona who omitted surgery and received endocrine therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adjuvant chemotherapy rate | 5 years after the last patient enrollment | 5 year adjuvant chemotherapy rate |
| invasive CBC rate | 5 years after the last patient enrollment | 5 year invasive contralateral breast cancer rate |
| OS | 5 years after the last patient enrollment | 5 year overall survival |
| BCSS | 5 years after the last patient enrollment | 5 year breast cancer specific survival |
| Change in health-related quality of life assessed by EORTC QLQ-C30 | At baseline, at 2 years, and at 5 years after the last patient enrollment | HRQoL will be evaluated using the EORTC QLQ-C30. Scores range from 0-100. Higher functional/global health scores indicate better QoL, while higher symptom scores indicate greater symptom burden. |
| Change in breast cancer-specific quality of life assessed by EORTC QLQ-BR23 | At baseline, at 2 years, and at 5 years after the last patient enrollment | Breast cancer-specific QoL will be assessed using the EORTC QLQ-BR23. Scores range from 0-100. Higher functional scores indicate better QoL; higher symptom scores indicate worse symptom burden. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse events associated with endocrine therapy and ovarian function suppression | From initiation of endocrine therapy to treatment discontinuation or last follow-up (up to 5 years after enrollment) | Incidence and severity of adverse events related to endocrine therapy and/or ovarian function suppression, graded according to CTCAE criteria. |
| Direct medical cost of active monitoring compared with standard therapy | 5 years after the last patient enrollment | Mean total direct medical cost (USD) incurred during 5-year follow-up will be compared between the active monitoring protocol and standard surgical management based on institutional billing data. |
| Incremental cost-effectiveness ratio (ICER) of active monitoring compared with standard therapy | 5 years after last patient enrollment. | Cost-effectiveness will be evaluated by the incremental cost-effectiveness ratio (ICER), calculated as cost per quality-adjusted life-year (QALY) gained for active monitoring versus standard therapy. |
| Change in circulating tumor DNA (ctDNA) detectability from baseline to surgery among participants who undergo surgery for invasive progression | Baseline and at time of surgery | Paired assessment of ctDNA detectability (present/absent) at baseline (diagnosis) and at the time of surgery among participants who progress to invasive breast cancer. Peripheral blood (20 mL) is collected at both time points. |
| Longitudinal detectability of circulating tumor DNA (ctDNA) at annual follow-up compared with baseline | Baseline (Day 1) and annually through study completion (up to 5 years) | Assessment of ctDNA detectability (present/absent) at baseline and at annual follow-up visits in all enrolled participants. Peripheral blood (20 mL) is collected at each time point. |
| Prognostic differences in invasive breast cancer progression according to age and type of endocrine therapy | 5 years after the last patient enrollment | Invasive breast cancer progression will be evaluated according to age at diagnosis and type of endocrine therapy. The proportion of participants who develop histologically confirmed invasive breast cancer during follow-up will be compared across subgroups defined by age and endocrine therapy regimen (tamoxifen, aromatase inhibitor, or combination with ovarian function suppression). |
Countries
South Korea
Contacts
Primary ContactJeong Eon Lee, MD, PhD
Outcome results
None listed